$13.73
00.00%
At Close: -
$13.67
-0.06-0.44%
After Hours: 1:04 PM EDT
15 minutes delayed
NeoGenomics
NEONASDAQ
NeoGenomics (NASDAQ:NEO) Stock, Analyst Ratings, Price Targets, Predictions
NeoGenomics Inc has a consensus price target of $20.57, established from looking at the 67 latest analyst ratings. The last 3 analyst ratings were released from BTIG, Benchmark, and TD Cowen on May 2, 2024, May 1, 2024, and May 1, 2024. With an average price target of $19.67 between BTIG, Benchmark, and TD Cowen, there's an implied 43.87% upside for NeoGenomics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BTIG
Benchmark
TD Cowen
Craig-Hallum
Needham
1calculated from analyst ratings
Analyst Ratings for NeoGenomics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/02/2024 | Buy Now | 53.62% | BTIG | Mark Massaro | $23 → $21 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 31.68% | Benchmark | Bruce Jackson | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2024 | Buy Now | 46.31% | TD Cowen | Dan Brennan | $21 → $20 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 90.2% | Craig-Hallum | Alex Nowark | → $26 | Assumes | → Buy | Get Alert |
| 04/30/2024 | Buy Now | 38.99% | Needham | Mike Matson | $24 → $19 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | 46.31% | Piper Sandler | David Westenberg | $18 → $20 | Maintains | Overweight | Get Alert |
| 02/22/2024 | Buy Now | 38.99% | Goldman Sachs | Matthew Sykes | $17 → $19 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | 75.57% | Needham | Mike Matson | $21 → $24 | Maintains | Buy | Get Alert |
| 12/29/2023 | Buy Now | 38.99% | TD Cowen | Dan Brennan | $22 → $19 | Maintains | Outperform | Get Alert |
| 12/29/2023 | Buy Now | 53.62% | BTIG | Mark Massaro | $25 → $21 | Maintains | Buy | Get Alert |
| 12/28/2023 | Buy Now | 53.62% | Needham | Mike Matson | → $21 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2023 | Buy Now | 24.36% | Morgan Stanley | Tejas Savant | $16 → $17 | Maintains | Equal-Weight | Get Alert |
| 11/07/2023 | Buy Now | 53.62% | Needham | Mike Matson | → $21 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | Buy Now | 17.04% | Morgan Stanley | Tejas Savant | $18 → $16 | Maintains | Equal-Weight | Get Alert |
| 10/23/2023 | Buy Now | 24.36% | Goldman Sachs | Matthew Sykes | $19 → $17 | Maintains | Buy | Get Alert |
| 10/20/2023 | Buy Now | 24.36% | Goldman Sachs | Matthew Sykes | $19 → $17 | Maintains | Buy | Get Alert |
| 10/16/2023 | Buy Now | 31.68% | Piper Sandler | David Westenberg | $23 → $18 | Maintains | Overweight | Get Alert |
| 08/21/2023 | Buy Now | 31.68% | Stephens & Co. | Jacob Johnson | $16 → $18 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 31.68% | Benchmark | Bruce Jackson | $20 → $18 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | 31.68% | Morgan Stanley | Tejas Savant | $19 → $18 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | 53.62% | Needham | Mike Matson | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | — | Raymond James | Andrew Cooper | — | Downgrade | Outperform → Market Perform | Get Alert |
| 05/10/2023 | Buy Now | 38.99% | Morgan Stanley | Tejas Savant | $18 → $19 | Maintains | Equal-Weight | Get Alert |
| 05/09/2023 | Buy Now | 82.88% | BTIG | Mark Massaro | → $25 | Upgrade | Neutral → Buy | Get Alert |
| 05/09/2023 | Buy Now | 60.94% | TD Cowen | Dan Brennan | $20 → $22 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 53.62% | Needham | Mike Matson | → $21 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 53.62% | Needham | Mike Matson | → $21 | Maintains | Buy | Get Alert |
| 04/11/2023 | Buy Now | 24.36% | B of A Securities | Derik De Bruin | $18 → $17 | Maintains | Neutral | Get Alert |
| 04/05/2023 | Buy Now | 53.62% | Needham | Mike Matson | → $21 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 46.31% | Piper Sandler | David Westenberg | $18 → $20 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 46.31% | Cowen & Co. | Dan Brennan | $14 → $20 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 31.68% | Morgan Stanley | Tejas Savant | $17 → $18 | Maintains | Equal-Weight | Get Alert |
| 02/24/2023 | Buy Now | 46.31% | Benchmark | Bruce Jackson | → $20 | Upgrade | Hold → Buy | Get Alert |
| 02/24/2023 | Buy Now | 38.99% | Raymond James | Andrew Cooper | $12 → $19 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 53.62% | Needham | Mike Matson | $15 → $21 | Maintains | Buy | Get Alert |
| 02/01/2023 | Buy Now | 9.73% | Needham | Mike Matson | → $15 | Upgrade | Hold → Buy | Get Alert |
| 11/14/2022 | Buy Now | 31.68% | Piper Sandler | David Westenberg | $19 → $18 | Maintains | Overweight | Get Alert |
| 11/11/2022 | Buy Now | -12.22% | Raymond James | Andrew Cooper | $15 → $12 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 24.36% | Morgan Stanley | Tejas Savant | $18 → $17 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | Buy Now | 9.73% | SVB Leerink | Puneet Souda | $12 → $15 | Maintains | Outperform | Get Alert |
| 08/26/2022 | Buy Now | — | Benchmark | Bruce Jackson | — | Downgrade | Buy → Hold | Get Alert |
| 08/22/2022 | Buy Now | — | Needham | Mike Matson | — | Downgrade | Buy → Hold | Get Alert |
| 08/17/2022 | Buy Now | 38.99% | Piper Sandler | David Westenberg | $13 → $19 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 31.68% | Morgan Stanley | Tejas Savant | $19 → $18 | Maintains | Equal-Weight | Get Alert |
| 08/10/2022 | Buy Now | 46.31% | Goldman Sachs | Matthew Sykes | $18 → $20 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 17.04% | Needham | Mike Matson | $19 → $16 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | -4.9% | Piper Sandler | David Westenberg | → $13 | Initiates | → Overweight | Get Alert |
| 04/28/2022 | Buy Now | 9.73% | Raymond James | Andrew Cooper | $18 → $15 | Maintains | Outperform | Get Alert |
| 04/18/2022 | Buy Now | 31.68% | Raymond James | Andrew Cooper | $24 → $18 | Maintains | Outperform | Get Alert |
| 04/12/2022 | Buy Now | 97.51% | Morgan Stanley | Tejas Savant | $29 → $27 | Maintains | Equal-Weight | Get Alert |
| 03/29/2022 | Buy Now | 31.68% | B of A Securities | Derik De Bruin | $25 → $18 | Downgrade | Buy → Neutral | Get Alert |
| 03/29/2022 | Buy Now | 75.57% | Cowen & Co. | Dan Brennan | $42 → $24 | Maintains | Outperform | Get Alert |
| 03/29/2022 | Buy Now | 104.83% | BTIG | Mark Massaro | $35 → $28 | Maintains | Buy | Get Alert |
| 03/29/2022 | Buy Now | 17.04% | Stephens & Co. | Jacob Johnson | $34 → $16 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/29/2022 | Buy Now | 38.99% | Needham | Mike Matson | $29 → $19 | Maintains | Buy | Get Alert |
| 03/29/2022 | Buy Now | 46.31% | SVB Leerink | Puneet Souda | $45 → $20 | Maintains | Outperform | Get Alert |
| 02/24/2022 | Buy Now | 112.14% | Morgan Stanley | Tejas Savant | $30 → $29 | Maintains | Equal-Weight | Get Alert |
| 02/24/2022 | Buy Now | 112.14% | Needham | Mike Matson | $41 → $29 | Maintains | Buy | Get Alert |
| 02/24/2022 | Buy Now | 75.57% | Raymond James | Andrew Cooper | $53 → $24 | Maintains | Outperform | Get Alert |
| 01/12/2022 | Buy Now | 229.19% | SVB Leerink | Puneet Souda | $50 → $45 | Maintains | Outperform | Get Alert |
| 12/16/2021 | Buy Now | 207.24% | Cowen & Co. | Dan Brennan | — | Initiates | → Outperform | Get Alert |
| 12/07/2021 | Buy Now | 199.93% | Needham | Mike Matson | — | Maintains | Buy | Get Alert |
| 11/05/2021 | Buy Now | 287.71% | Stephens & Co. | Jacob Johnson | — | Maintains | Overweight | Get Alert |
| 11/05/2021 | Buy Now | 251.13% | Needham | Mike Matson | — | Maintains | Buy | Get Alert |
| 11/05/2021 | Buy Now | 338.92% | SVB Leerink | Puneet Souda | — | Maintains | Outperform | Get Alert |
| 10/14/2021 | Buy Now | — | Raymond James | Andrew Cooper | — | Upgrade | Market Perform → Outperform | Get Alert |
| 08/09/2021 | Buy Now | 324.29% | Morgan Stanley | — | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for NeoGenomics (NEO) stock?
The latest price target for NeoGenomics (NASDAQ:NEO) was reported by BTIG on May 2, 2024. The analyst firm set a price target for $21.00 expecting NEO to rise to within 12 months (a possible 53.62% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeoGenomics (NEO)?
The latest analyst rating for NeoGenomics (NASDAQ:NEO) was provided by BTIG, and NeoGenomics maintained their buy rating.
When was the last upgrade for NeoGenomics (NEO)?
The last upgrade for NeoGenomics Inc happened on August 21, 2023 when Stephens & Co. raised their price target to $18. Stephens & Co. previously had an equal-weight for NeoGenomics Inc.
When was the last downgrade for NeoGenomics (NEO)?
The last downgrade for NeoGenomics Inc happened on May 16, 2023 when Raymond James changed their price target from N/A to N/A for NeoGenomics Inc.
When is the next analyst rating going to be posted or updated for NeoGenomics (NEO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeoGenomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeoGenomics was filed on May 2, 2024 so you should expect the next rating to be made available sometime around May 2, 2025.
Is the Analyst Rating NeoGenomics (NEO) correct?
While ratings are subjective and will change, the latest NeoGenomics (NEO) rating was a maintained with a price target of $23.00 to $21.00. The current price NeoGenomics (NEO) is trading at is $13.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.